



**Health and
Disability Ethics
Committees**

**Northern A Health and Disability
Ethics Committee
Annual Report
2025**

Contents

About this report3

About the committee3

Approvals and registrations3

Chairperson’s report.....4

Applications reviewed6

Summary of applications received by full ECError! Bookmark not defined.

Complaints and overdue application summary7

Timeliness review8

DETAILS OF APPLICATIONS Error! Bookmark not defined.

About this report

This report is a summary of the activities of the Northern A Health and Disability Ethics Committees (HDEC) for the period of 01 July 2024 – 30 June 2025. It includes a summary of the applications reviewed during the year, details of any complaints received (and how they were resolved), and a list of new applications submitted.

About the committee

The Northern A Health and Disability Ethics Committees (HDEC) is a Ministerial committee established under section 87 of the [Pae Ora \(Healthy Futures\) Act 2022](#). Its members are appointed by the Minister of Health through the public appointments process.

The primary function of the Committee is to provide independent ethical review of health research and innovative practice in order to safeguard the rights, health and wellbeing of consumers and research participants and, in particular, those persons with diminished autonomy by checking that it meets or exceeds established [ethical standards](#).

Approvals and registrations

The Southern HDEC is approved by the Health Research Council Ethics Committee for the purposes of section 25(1)(c) of the [Health Research Council Act 1990](#).

The Southern HDEC is registered (number IRB00008713) with the United States' [Office for Human Research Protections](#). This registration enables the committee to review research conducted or supported by the US Department of Health and Human Services.

Chairperson's report

This report presents a collective overview of the work of the Health and Disability Ethics Committees (HDECs) for the year ending 30 June 2025.

Over the reporting period, the HDECs have continued to operate effectively and in accordance with the Health Research Council (HRC) expectations and the National Ethical Standards. Despite ongoing pressures, the Committees have remained committed to providing robust and fit-for-purpose ethical review of health and disability research in New Zealand.

At various points during the year, some committees experienced challenges with member numbers and recruitment, particularly for non-lay members with specific clinical expertise. However, a non-lay recruitment round in June 2025 hopes to address the difficulties with member numbers. Prior to this recruitment members regularly co-opted to support quorum requirements, assist with workloads, and undertake post-approval reviews. This shared approach has been essential to maintaining continuity and consistency of decision-making across the system.

Committee members collectively bring a broad range of expertise and experience. Over the year, the HDECs have continued to engage constructively with research organisations and sponsors to improve understanding of ethical requirements, particularly the application of the National Ethical Standards to study design, consent processes, participant protections, and document submission expectations. While progress has been made, there remains variable awareness among researchers of the guidance, templates, and resources available through the HDEC website, and continued education in this area would be beneficial.

A consistent focus of ethical review has been the quality of participant information and informed consent. Committees have continued to scrutinise overly long or complex information sheets, encourage the use of participant-friendly formats, and require clear distinction between research activities and standard clinical care in New Zealand. Risks are expected to be accurately described and benefits not overstated, including avoiding the use of therapeutic language for investigational or experimental interventions.

The volume and complexity of applications remain high, reflecting the strength of the New Zealand research environment and its ongoing attractiveness to international sponsors. To maintain this appeal, and to be sure that the benefits of research remain in New Zealand the Chairs note that it is important to continue to invest public good funding into a research-ready workforce and NZ-initiated projects. Attendance by researchers and sponsors at meetings has been increasingly common and is strongly valued, as it supports meaningful ethical dialogue and efficient resolution of issues. At the same time, the workload associated with full committee review remains significant, particularly in an online meeting environment. Consideration of refinements to review pathways, or revisions of the current HDEC SOP, may assist in managing volumes while maintaining ethical rigour.

Rapid scientific and technological developments continue to shape the ethical landscape. Applications involving artificial intelligence, algorithm development, and advanced data use are increasing. Ensuring that such research is appropriately captured within HDEC review and governance structures remains an emerging challenge.

Throughout the year, Chairs have continued to meet regularly, providing an important forum for sharing knowledge, aligning practice, and receiving updates from the Secretariat.

Strengthened relationships with advisory and assessment bodies, as well as opportunities for practical training and development for members, would further support consistent and high-quality ethical review in an increasingly complex research environment.

The work of the HDECs would not be possible without the dedication of the Secretariat. The Secretariat has continued to provide high-quality advice, coordination, and support under significant resourcing constraints and ongoing uncertainty. With a small team supporting a large membership and substantial application volumes, their professionalism, expertise, and commitment have been critical to the effective functioning of the committees. Adequate and sustainable resourcing of this support remains essential.

Finally, sincere thanks are extended to all committee members, who balance substantial ethics workloads alongside their professional roles, and to the sponsors, researchers, and coordinators who engage constructively with the ethical review process. Their commitment to scientific integrity, respectful engagement, and high ethical standards contributes to New Zealand's reputation as an excellent place to conduct health and disability research.

The HDECs look forward to continuing this work in the coming year, in support of ethical research that advances the health and wellbeing of all New Zealanders.

Applications reviewed

Summary of applications received by full EC.

No. of applications approved at first review	0
No. of applications approved subject to conditions	16
No. of applications where further information was requested prior to granting approval	49
No. of applications deferred/asked to resubmit and subsequently approved	46
No. of applications currently seeking further information/deferred/asked to resubmit as at time of this report	3
No. of applications declined	8
No. of applications which do not require ethics committee approval	767
No. of applications withdrawn by researcher	2
No. of applications terminated by sponsor	0
No. of applications transferred to another EC	0
Total number of applications received by full EC	75

Summary of applications received under expedited / low risk review.

(All outcomes refer to outcome of first review.)

No. of applications approved	0
No. of applications approved subject to conditions / seeking further information / pended / asked to resubmit	12
No. of applications which do not require ethics committee approval	767
No. of applications referred for full committee review	2
No. of applications declined	1
Total number of applications received under expedited / low risk review	13

Total number of applications received.

88

Complaints and overdue application summary

This section outlines complaints about decisions made by the Committee during 2024.

Complaints received

Received 29/05/2025:

Complaint from participant who indicated that consent was given by partner/whānau not themselves. The noted that Partners/whānau are only mentioned as people to discuss this study with or to support the decision to consent, not as substitute consenters. The Chair was notified and confirmed that we did not receive any protocol deviations while the study was open, for this specific incident or otherwise. At the time of the complaint the study had been closed and little action could be made from HDEC. This complaint highlighted the responsibilities for research staff and the detail in which protocol documents need to describe consenting practices. Moving forward the HDEC can apply understandings from this study and incident to future research involving the same, or similar, participant groups. Extra considerations around consent process in the study protocols can be taken during HDEC review.

Received 25/02/2025:

A complaint was received by a trial participant who believed they were wrongly withdrawn from a study. The Secretariat reached out to the study team to understand the circumstances of the participant's termination of study participation. Correspondence with the study team clarified that termination of study participation was within exclusion criteria and research teams remit. HDEC Concluded that there has not been an ethical breach of the NEAC standards and that the study team were operating within their approved study protocol.

Received 11/03/2025:

A complaint was received regarding an individual who had booked flights before payment by the research team as the complainant no longer wanted to participate if they were to be in a randomised double-blind trial with no guarantee of receiving the intervention. The complainant cannot get a refund on flights booked in 2021. HDEC Concluded that there has not been an ethical breach of the NEAC standards and that the study team were operating within their approved study protocol.

Received 05/11/2024:

A complaint was received by a trial participant who believed they were mistreated during their time on the study. The Study team was contacted regarding the complaint and disputed the complainants account of mistreatment. HDEC determined that contacting the HDC was the best pathway for this complainant and responded with this to the complainant.

Received 17/09/2024:

The complaint outlines the participants concerns about the pre-screening process, training of staff performing the pre-screening and subsequent vaccination, believed to be part of the study. The participant felt distressed and is concerned that the vaccinations might cause health risks or interfere with their contraception. The Participant was assured by their Dr that the vaccine administered is approved for use. HDEC contacted the study team to clarify and confirm if there are any planned updates to their process because of the complaint. The study team provided several possible opportunities for improvement because of this complaint. HDEC responded to the complainant and indicated they could contact HDC advocacy for further support.

Received 26/06/2024:

The complaint was made to HDEC regarding concerns around the omission of a death from a study publication. The complainant explained that they believe that protocol changes, following a pause in the study and ethical review, have been used to retrospectively exclude

this patient from the trial and publication. HDEC determined that the study team had notified HDEC of the death and followed correct processes. HDEC await the final report of the study which would allow the Chair to discuss the concerns and find reassurance or raise further ethical concerns.

Timeliness review

Average review times take into account the time taken for the Secretariat to process applications and the time taken for the Committee to review applications. The clock is stopped when a decision letter is emailed to applicants. Average review times exclude time taken for researchers to respond to requests for further information. Researchers have up to 90 days to respond.

Average review time was 31 days for expedited applications. Target timeframe for expedited applications is 15 calendar days (Standard Operating Procedures for Health and Disability Ethics Committees, para 9-102). The reason for this average being higher than the target was due to limited resourcing, Secretariat delays in being able to process the letters following review by the sub-committee, and the busy schedule of the Chair which limits their availability to complete reviews.

Average review time was 43 days for full applications. Target timeframe for full applications is 35 days. (Standard Operating Procedures for Health and Disability Ethics Committees, para 54-59). The reason for this average being higher than the target was due to limited resourcing, Secretariat delays in being able to process the letters following review, and the busy schedule of Provisional Approval reviewers which impacts their availability to complete reviews.

Appendix 1: Details of applications reviewed¹

SECTION 9: DETAILS OF APPLICATIONS

Reference no.	Protocol title	Name of principal investigator	Date received	Date of first review	Outcome of first review	Status at time of report	Date of final outcome	Indicate if HRC funded (
2025 FULL 22079	COBRA - COrticosteroids for Biphasic Reactions in Anaphylaxis	Dr Adrian Owen	18/12/2024	3/03/2025	Archived	Approved	8/08/2025	No
2025 FULL 21521	GBP560_001: A Phase I/II Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults.	Dr Cory Sellwood	22/11/2024	3/03/2025	Archived	Approved	3/06/2025	No
2024 FULL 20420	ALLG NHL38 EPCOR Sandwich	Dr Leanne Berkahn	7/08/2024	6/09/2024	Archived	Approved	26/02/2025	No
2024 FULL 21158	206867: A study to compare the effects of FF/UMEC/VI with FF/VI in 12-17 year-olds with asthma	Dr Paul Hamilton	20/09/2024	7/11/2024	Archived	Approved	4/02/2025	No
2025 FULL 21223	Evidencing the causal mechanisms of Kaupapa Māori health transformation	Associate Professor Sacha McMeeking	17/10/2024	3/03/2025	Archived	Approved	4/04/2025	Yes
2025 FULL 21735	OD-07656-201: A Phase 2a Study of OD-07656 and Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis	Dr Paul Hamilton	11/12/2024	3/03/2025	Archived	Approved	2/04/2025	No
2025 FULL 21764	Australia and New Zealand Lung Transplant Registry (ANZLUNG)	Dr Sasiharan Sitamparanathan	5/12/2024	3/03/2025	Archived	Approved	4/04/2025	No
2025 FULL 21799	A trial of the QCore tinnitus therapy system.	Professor Grant Searchfield	2/05/2025	9/06/2025	Archived	Approved	2/09/2025	No
2025 FULL 21551	A Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC	Dr David Gibbs	16/12/2024	3/03/2025	Archived	Approved	24/04/2025	No

¹ Data is directly reported from the online system. Any errors in spelling is reflected due to errors made by the applicant.

2025 FULL 21756	ELITE-BTK Trial	Dr Andrew Holden	13/12/2024	3/03/2025	Archived	Approved	21/03/2025	No
2025 FULL 18376	The Dragon 2 Trial	Doctor Rukshan Fernando	17/12/2024	3/03/2025	Archived	Approved	8/05/2025	No
2025 FULL 21477	Prosthetic Joint Infection Trial (ROADMAP)	Dr Thomas Hills	5/03/2025	9/05/2025	Archived	Approved	16/06/2025	Yes
2025 FULL 22492	BGB-11417-303_Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Dr. Sarah Tan	21/03/2025	9/05/2025	Archived	Approved	3/07/2025	No
2024 FULL 21748	AROALK7-1001: A Study to Evaluate ARO-ALK7 in Adult Volunteers with Obesity With and Without Type 2 Diabetes.	Dr Christian Schwabe	13/12/2024	3/03/2025	Approved	Approved	3/03/2025	No
2024 FULL 21892	PX578-001: A Study to Evaluate PX578 in Healthy Adults	Dr Chris Wynne	13/12/2024	3/03/2025	Approved	Approved	3/03/2025	No
2025 FULL 21953	The A.R.R.E.S.T. study (NZ)	Dr Jagrut Lallu	13/02/2025	28/03/2025	Archived	Approved	10/06/2025	No
2025 FULL 21395	Quality of life for children with retinal dystrophy	Dr Sarah Hull	24/09/2024	7/11/2024	Archived	Approved	1/04/2025	No
2025 FULL 20953	International Intestinal Failure Registry	Dr Amin Roberts	2/08/2024	6/09/2024	Archived	Approved	10/03/2025	No
2025 EXP 22533	Kai Āhū Nuku	Dr Nicola Gillies	21/03/2025	9/05/2025	Archived	Approved	10/06/2025	No
2024 FULL 21181	DR-0201-AIM-001: A Study to Evaluate DR-0201 in Patients with Select Autoimmune Rheumatic Diseases	Dr Paul Graham Hamilton	4/09/2024	23/09/2024	Archived	Approved	2/12/2024	No
2025 FULL 22496	Decide Trial. Dexmedetomidine to reduce post-op delirium in Cardiac Surgery.	Dr Amy Gaskell	5/05/2025	9/06/2025	Archived	Approved	2/09/2025	No
2025 FULL 23083	1378-0041: A study to test vicadrostal (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure, and cardiovascular disease.	Professor Richard Troughton	28/05/2025	7/07/2025	Archived	Approved	13/08/2025	No
2025 FULL 21847	Australia and New Zealand Heart Transplant Registry (ANZHTR)	Dr Thomas Pasley	26/03/2025	9/05/2025	Archived	Approved	3/07/2025	No
2025 FULL 22184	D5241C00007-JOURNEY: A study to investigate the efficacy and safety of tezepelumab in adult	Dr Syed Hussain	24/02/2025	28/03/2025	Archived	Approved	5/05/2025	No

	participants with moderate to very severe COPD (HDEC Application)							
2025 FULL 22231	Visual and Academic Functions after Amblyopia Treatment	Dr Tina Gao	2/05/2025	9/06/2025	Archived	Approved	3/09/2025	No
2024 FULL 21354	MK-4482-023: A Phase 3 Study of MK-4482 in Non-Hospitalised Adults With COVID-19 at High Risk for Disease Progression	Dr Claire Thurlow	24/09/2024	7/11/2024	Archived	Approved	2/12/2024	No
2025 EXP 22611	The role of physiotherapy rehabilitation in improving health outcomes for Māori with matepukupuku.	Ms Rachel Swann	16/04/2025	9/06/2025	Archived	Approved	23/07/2025	Yes
2024 FULL 21078	A Study to Investigate Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adult Patients With Relapsed/Refractory Mantle Cell Lymphoma.	Dr Marie Hughes	23/09/2024	7/11/2024	Archived	Approved	26/11/2024	No
2025 FULL 22031	How different mask designs affect people's breathing in COPD and OHS patients using long-term home ventilation.	Dr William Good	13/02/2025	28/03/2025	Archived	Approved	2/05/2025	No
2025 FULL 22383	The iLet BP Algorithms Study	A/Prof Martin de Bock	19/02/2025	28/03/2025	Archived	Approved	23/04/2025	No
2025 FULL 22752	A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.	Dr Rory Bennett	5/05/2025	9/06/2025	Archived	Approved	11/07/2025	No
2025 FULL 21774	RELATIVITY 1093: Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy in Participants with Non-squamous Stage IV or Recurrent NSCLC and PD-L1 ≥ 1%	Dr Aileen Ludlow	3/04/2025	9/05/2025	Archived	Approved	14/08/2025	No
2025 EXP 21216	A One Health Approach to Investigating Leptospira in Aotearoa New Zealand	Prof Jackie Benschop	17/04/2025	9/06/2025	Archived	Approved	8/09/2025	No
2025 EXP 22353	STEP-FMD: Study of Transcranial Magnetic Stimulation Enhanced Physiotherapy for people with Functional Movement Disorder.	Prof Cathy Stinear	28/04/2025	9/06/2025	Archived	Approved	4/07/2025	No
2024 FULL 21128	AROINHBE-1001: A Study To Evaluate ARO-INHBE in Adult Volunteers with Obesity With and Without Type 2 Diabetes.	Dr Rinki Murphy	24/09/2024	7/11/2024	Archived	Approved	26/11/2024	No
2025 EXP 22070	Track-PINK1 PD	Dr Viswas Dayal	23/04/2025	9/06/2025	Archived	Approved	16/07/2025	No

2025 EXP 22865	Can applying castor oil to the eyelids improve dry eye?	Professor Jennifer Craig	8/05/2025	2/07/2025	Approved	Approved	2/07/2025	No
2025 EXP 22583	Biologic Options for Optimal Second-line Treatment for fistulising Crohn's Disease	Doctor Abhimati Ravikulan	13/05/2025	7/07/2025	Declined	Declined	7/07/2025	No
2025 FULL 22962	Double-blind study of RG6496 in Huntington's disease participants	Professor Tim Anderson	28/05/2025	7/07/2025	Archived	Approved	1/08/2025	No
2025 EXP 19812	MindArt for stroke survivors and supporters	Dr Susan Gee	14/05/2025	7/07/2025	Approved	Approved	7/07/2025	Yes
2025 FULL 22011	MAV1: Endograft Treatment of Aortic Disease	Mr Manar Khashram	12/02/2025	28/03/2025	Archived	Approved	4/06/2025	No
2025 EXP 22216	Te Iti Kahurangi: Neonatal mortality and morbidity among term pA*pi	Associate Professor Liza Edmonds	17/04/2025	9/06/2025	Declined	Declined	9/06/2025	Yes
2025 EXP 22969	Outcomes in young adults with diabetes living in the Auckland region - a retrospective cohort study (final version)	Dr James Devoe	20/05/2025	2/07/2025	Archived	Approved	1/08/2025	No
2024 FULL 21027	ITL-2002-CL-301: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)	Dr Hilary Longhurst	18/09/2024	7/11/2024	Approved	Approved	7/11/2024	No
2024 FULL 20152	Natural History Study of Exocrine Pancreatic Function in Infants With CF (VX24-445-130)	Dr Samuel Dalton	4/07/2024	6/08/2024	Archived	Approved	13/09/2024	No
2024 FULL 20840	TX000045-003: A 24-Week Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF) (the APEX Study)	Dr Richard Troughton	25/07/2024	6/09/2024	Archived	Approved	7/10/2024	No
2024 FULL 19952	Viber-MM25: A phase Ib/II study of Venetoclax, Iberdomide and Dexamethasone for patients in first or second relapse of Multiple Myeloma with t(11;14)	Dr Nicole Chien	8/08/2024	6/09/2024	Archived	Approved	26/11/2024	No
2024 FULL 21079	218309 B-United: A study of sequential therapy with daplusiran/tomligisiran followed by bepirovirsen in people living with chronic hepatitis B.	Professor Edward Gane	22/08/2024	23/09/2024	Archived	Approved	8/11/2024	No
2024 FULL 21279	GuiDIng energy provision using indiREct CalorimeTry - DIRECT trial	Ms Varsha Asrani	23/09/2024	7/11/2024	Declined	Declined	7/11/2024	No
2025 FULL 22735	CND261-101 A Phase 1b study of CND261 in Seropositive Rheumatoid Arthritis	Dr Paul Hamilton	7/05/2025	9/06/2025	Archived	Approved	21/07/2025	No
2025 EXP 22662	The EOCRC Network Aotearoa	Dr Tamara Glyn	4/06/2025	7/07/2025	Archived	Approved	1/09/2025	No

2025 EXP 22750	The WISE study	Ms Emma Le Lievre	16/06/2025	18/07/2025	Archived	Approved	1/09/2025	No
2024 FULL 20663	Safety and Efficacy of balloon dilation for Improvement of Swallowing in Patients with Upper Esophageal Sphincter obstruction	Associate Professor Jacqui Allen	1/07/2024	6/08/2024	Archived	Approved	19/08/2024	No
2024 FULL 20784	D346BC00001: A 2-stage, Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus	Professor Marius Rademaker	7/08/2024	6/09/2024	Archived	Approved	22/11/2024	No
2024 FULL 20814	stAAAbLe Trial	Dr Andrew Holden	31/07/2024	6/09/2024	Archived	Approved	7/10/2024	No
2024 FULL 20966	Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose (AER-01) in Adults with Chronic Obstructive Pulmonary Disease.	Dr Michael Epton	4/09/2024	23/09/2024	Archived	Approved	1/11/2024	No
2024 FULL 20673	A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures	Dr Beatriz Romero Ferrando	5/09/2024	23/09/2024	Archived	Approved	8/11/2024	No
2024 FULL 19391	Whiria te hohenga - Supportive cancer care - a feasibility study	Ms Jeannine Stairmand	25/09/2024	7/11/2024	Approved	Approved	7/11/2024	No
2025 EXP 21437	Atypical endometrial hyperplasia (AEH) and outcomes	Associate Professor Michelle Wise	22/05/2025	3/07/2025	Provisionally Approved	Provisionally Approved	3/07/2025	No
2024 FULL 21086	Phase 1/2 Basket Study of HER3-DXd in GI Cancers	Dr. Sanjeev Deva	4/09/2024	23/09/2024	Archived	Approved	22/11/2024	No
2025 FULL 22206	Continuous Glucose monitoring for Type 2 Diabetes in Pregnancy: a Feasibility Study	Dr Charlotte Oyston	24/02/2025	28/03/2025	Archived	Approved	24/04/2025	No
2025 FULL 22600	NEU-627-MS101: A Study to Evaluate NEU-627 in Healthy Volunteers	Dr Leanne Barnett	1/04/2025	9/05/2025	Approved	Approved	9/05/2025	No
2025 FULL 21130	Closure of emergency midline abdominal incisions	Doctor Henry Witcomb Cahill	1/04/2025	9/05/2025	Provisionally Approved	Provisionally Approved	9/05/2025	No
2025 FULL 22729	SWiFT Aotearoa	Dr Richard Charlewood	4/04/2025	9/05/2025	Declined	Declined	9/05/2025	No
2025 FULL 22556	Neonatal unit patient responses to oxygen therapy	Dr Daniel Mackay	5/05/2025	9/06/2025	Approved	Approved	9/06/2025	No
2024 FULL 20602	NEU-111-UC101: A Study to Evaluate NEU-111 in Healthy Participants	Dr Leanne Barnett	3/07/2024	6/08/2024	Approved	Approved	6/08/2024	No
2024 FULL 20593	BJT-628-001: A Study to Evaluate BJT-628 in Single and Multiple Doses in Healthy Participants	Professor Edward Gane	3/07/2024	6/08/2024	Approved	Approved	6/08/2024	No

	and in Participants with Chronic Hepatitis B (CHB) and Chronic Hepatitis D (CHD) Infection.							
2025 FULL 22514	Bioengineered Animal Tissue Graft Sling Study	Clinical Associate Professor Michael Stitely	6/05/2025	9/06/2025	Declined	Declined	9/06/2025	No
2025 FULL 22131	REPORT Study	Dr Kalpa Jayanatha	6/05/2025	9/06/2025	Declined	Declined	9/06/2025	Yes
2025 FULL 22904	Oral ketamine for bipolar depression - resubmission post decline	Associate Professor Ben Beaglehole	7/05/2025	9/06/2025	Approved	Approved	9/06/2025	No
2025 EXP 22835	Metabolic health of Parkinson's disease patients who underwent deep brain stimulation surgery: a retrospective cohort study	Dr Fiona Lithander	23/05/2025	25/06/2025	Approved	Approved	25/06/2025	No
2025 FULL 22942	FB102-301: A Phase 2 study evaluating safety and efficacy of FB102 in participants with coeliac disease on gluten-free diet.	Dr Paul Hamilton	8/05/2025	9/06/2025	Approved	Approved	9/06/2025	No
2025 FULL 22134	OCEANic: Osimertinib plus Chemotherapy Evaluation in Adjuvant NSCLC incorporating CtDNA	Dr Alice Minhinnick	8/05/2025	9/06/2025	Approved	Approved	9/06/2025	No
2025 EXP 21330	Trends in overall survival rates in women diagnosed with ovarian cancer in New Zealand: a follow-up study	Doctor Faye Riley	17/06/2025	18/07/2025	Approved	Approved	18/07/2025	No
2025 FULL 22237	Exploring the use of a new testing method that looks for genetic material of microorganisms possibly present in spinal fluid samples received in a New Zealand clinical laboratory.	Miss Delphine Marjoshi	26/02/2025	28/03/2025	Declined	Declined	28/03/2025	No
2025 FULL 22303	BJT-778-301: A Study to Evaluate BJT-778 in Participants with Chronic Hepatitis Delta Virus (HDV) Infection.	Professor Edward Gane	27/02/2025	28/03/2025	Approved	Approved	28/03/2025	No
2025 FULL 22372	A Study to Assess KRRO-110 in Healthy Participants and in Participants with Alpha-1 Antitrypsin Deficiency (AATD)	Dr Mark O'Carroll	27/02/2025	28/03/2025	Approved	Approved	28/03/2025	No
2025 FULL 23080	SWIFT Aotearoa for HDEC	Dr Richard Charlewood	8/06/2025	7/07/2025	Approved	Approved	7/07/2025	No
2025 FULL 23377	TRX-100-0002: A Study to Evaluate Different Oral Doses of TRX-100 and Standard of Care in Participants with Influenza	Dr James Stanley	26/06/2025	25/07/2025	Declined	Declined	25/07/2025	No

2025 FULL 23158	TERN-701-1012 - Participants with Chronic Myeloid Leukemia (CML)/Phase 1	Professor Peter John Browett	26/06/2025	25/07/2025	Provisionally Approved	Provisionally Approved	25/07/2025	No
2025 FULL 22549	RASolve 301: Phase 3 Study of RMC-6236 in Previously Treated NSCLC Patients with RAS Mutation	Dr Laird Cameron	26/06/2025	25/07/2025	Provisionally Approved	Provisionally Approved	25/07/2025	No
2025 FULL 22165	GS-US-409-5704: Study of GS-1427 In Participants With Moderately To Severe Active Ulcerative Colitis	Dr Paul Hamilton	28/02/2025	28/03/2025	Approved	Approved	28/03/2025	No
2025 FULL 22585	A pilot implementation study of a telehealth intervention aimed at improving adolescent outcomes following acquired brain injury	Associate Professor Kelly Jones	30/06/2025	25/07/2025	Archived	Approved	27/08/2025	No
2025 FULL 22169	Using Empathic Characters for Virtual Cognitive Rehabilitation	Professor Mark Billingham	30/06/2025	25/07/2025	Declined	Declined	25/07/2025	No
2024 FULL 21219	Comparison of two Iron polymaltose tablets under fed conditions	Dr Noelyn Hung	5/09/2024	23/09/2024	Approved	Approved	23/09/2024	No
2024 FULL 21282	Vagus nerve stimulation for tinnitus.	Professor Dirk De Ridder	5/09/2024	23/09/2024	Declined	Declined	23/09/2024	No
2024 FULL 21112	Phase 2 Study Investigating Efficacy and Safety of Sonrotoclax Plus Azacitidine Versus Venetoclax Plus Azacitidine in Patients With Acute Myeloid Leukaemia Who Ineligible for Intensive Chemotherapy	Ms Sophie Leitch	30/08/2024	13/09/2024	Withdrawn by Researcher	Withdrawn by Researcher	13/09/2024	No
2025 FULL 22247	S-2A Microdosing for perioperative pain management	Honorary Professor Timothy Short	26/06/2025	9/07/2025	Withdrawn by Researcher	Withdrawn by Researcher	9/07/2025	No